Our study provides a comprehensive insight into the efficacy of Nrf2 activation in Alport syndrome and provides a rationale for adding a Keap1-Nrf2 interaction inhibitor to a renin–angiotensin system inhibitor. Here, KEAP1 is linked to Alport syndrome.